FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655100> ?p ?o ?g. }

• W4385655100 endingPage "e40906a2" @default.
• W4385655100 startingPage "e40906a2" @default.
• W4385655100 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a component of the MALT1-BCL10-CARD11 complex downstream from the Bruton Tyrosine Kinase (BTK) on the B-cell receptor signaling pathway. MALT1 is a key mediator of the nuclear factor kappa B (NF-κB) signaling, which is the main driver of a subset of B-cell lymphomas. MALT1 is considered a potential therapeutic target for several subtypes of non-Hodgkin B-cell lymphomas and chronic lymphocytic leukemia (CLL), including tumors with acquired BTK inhibitor (BTKi) resistance. Constitutive activation of the NF-κB is a molecular hallmark of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), and MALT1 may have utility as a treatment option for ABC-DLBCL. SGR-1505 is an oral potent small molecule allosteric inhibitor of MALT1 that inhibits MALT1 enzymatic activity and demonstrates anti-proliferative activity in ABC-DLBCL cell lines, both BTKi-sensitive (OCI-LY10) and BTKi-resistant (OCI-LY3). SGR-1505 administered as a single agent and in combination with the approved Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, demonstrates tumorostatic and regressive antitumor activity in ABC-DLBCL cell line-derived xenograft and patient-derived xenograft models. Aims: These data suggest that SGR-1505-mediated MALT1 inhibition has therapeutic potential and may expand therapeutic options for patients with selected B-cell lymphomas supporting further evaluation of SGR-1505 in clinical trials. Methods: SGR-1505-101 (NCT05544019) is a phase 1, multicenter trial of SGR-1505 as monotherapy in subjects with mature B-cell malignancies. At present, the study has been activated in 3 sites in the United States. The primary objective is to evaluate safety and tolerability of SGR-1505 as monotherapy and to identify the maximum tolerated dose (MTD) and/or recommended dose (RD). Secondary objectives are to evaluate the pharmacokinetic (PK) profile, food effect, drug-drug interaction, and preliminary anti-tumor activity of SGR-1505. Key inclusion criteria are: history of mature B-cell malignancy (including aggressive and indolent B-cell lymphomas, Waldenström macroglobulinemia, and CLL); measurable or detectable disease according to the applicable disease-specific classification system (Lugano, iwCLL, WWM6); Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. Patients with indolent B-cell lymphomas or CLL must have an indication for treatment and not require immediate cytoreductive therapy. Subjects with symptomatic or active CNS involvement, and other conditions or laboratory findings placing them at increased risk to the use of an investigational drug are excluded. SGR-1505 is initially dose-escalated using an accelerated titration design in cohorts of 1-6 subjects, and at higher dose levels using a conventional 3 + 3 design. Results: SGR-1505-101, a phase 1, open-Label, multicenter, dose-escalation study of SGR-1505 as monotherapy in subjects with mature B-cell malignancies is active. Summary/Conclusion: Preclinical data suggest that SGR-1505 as a potent and well tolerated MALT1 inhibitor may provide therapeutic options for patients with select B-cell lymphomas. The overall risk-benefit of evaluating SGR-1505 in the clinical setting remains favorable. Keywords: Diffuse large B cell lymphoma, B cell lymphoma, Clinical trial, Chronic lymphocytic leukemia" @default.
• W4385655100 created "2023-08-09" @default.
• W4385655100 creator A5009121120 @default.
• W4385655100 creator A5013019154 @default.
• W4385655100 creator A5014691228 @default.
• W4385655100 creator A5026235385 @default.
• W4385655100 creator A5039964251 @default.
• W4385655100 creator A5040123502 @default.
• W4385655100 creator A5058210944 @default.
• W4385655100 creator A5079354153 @default.
• W4385655100 creator A5087957313 @default.
• W4385655100 creator A5090024030 @default.
• W4385655100 date "2023-08-01" @default.
• W4385655100 modified "2023-09-26" @default.
• W4385655100 title "PB2349: A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES" @default.
• W4385655100 doi "https://doi.org/10.1097/01.hs9.0000976116.40906.a2" @default.
• W4385655100 hasPublicationYear "2023" @default.
• W4385655100 type Work @default.
• W4385655100 citedByCount "0" @default.
• W4385655100 crossrefType "journal-article" @default.
• W4385655100 hasAuthorship W4385655100A5009121120 @default.
• W4385655100 hasAuthorship W4385655100A5013019154 @default.
• W4385655100 hasAuthorship W4385655100A5014691228 @default.
• W4385655100 hasAuthorship W4385655100A5026235385 @default.
• W4385655100 hasAuthorship W4385655100A5039964251 @default.
• W4385655100 hasAuthorship W4385655100A5040123502 @default.
• W4385655100 hasAuthorship W4385655100A5058210944 @default.
• W4385655100 hasAuthorship W4385655100A5079354153 @default.
• W4385655100 hasAuthorship W4385655100A5087957313 @default.
• W4385655100 hasAuthorship W4385655100A5090024030 @default.
• W4385655100 hasBestOaLocation W43856551001 @default.
• W4385655100 hasConcept C126322002 @default.
• W4385655100 hasConcept C143998085 @default.
• W4385655100 hasConcept C159654299 @default.
• W4385655100 hasConcept C170493617 @default.
• W4385655100 hasConcept C203014093 @default.
• W4385655100 hasConcept C2777525834 @default.
• W4385655100 hasConcept C2777938653 @default.
• W4385655100 hasConcept C2778453870 @default.
• W4385655100 hasConcept C2778461978 @default.
• W4385655100 hasConcept C2779338263 @default.
• W4385655100 hasConcept C2779878957 @default.
• W4385655100 hasConcept C42362537 @default.
• W4385655100 hasConcept C502942594 @default.
• W4385655100 hasConcept C71924100 @default.
• W4385655100 hasConcept C86803240 @default.
• W4385655100 hasConcept C90059517 @default.
• W4385655100 hasConceptScore W4385655100C126322002 @default.
• W4385655100 hasConceptScore W4385655100C143998085 @default.
• W4385655100 hasConceptScore W4385655100C159654299 @default.
• W4385655100 hasConceptScore W4385655100C170493617 @default.
• W4385655100 hasConceptScore W4385655100C203014093 @default.
• W4385655100 hasConceptScore W4385655100C2777525834 @default.
• W4385655100 hasConceptScore W4385655100C2777938653 @default.
• W4385655100 hasConceptScore W4385655100C2778453870 @default.
• W4385655100 hasConceptScore W4385655100C2778461978 @default.
• W4385655100 hasConceptScore W4385655100C2779338263 @default.
• W4385655100 hasConceptScore W4385655100C2779878957 @default.
• W4385655100 hasConceptScore W4385655100C42362537 @default.
• W4385655100 hasConceptScore W4385655100C502942594 @default.
• W4385655100 hasConceptScore W4385655100C71924100 @default.
• W4385655100 hasConceptScore W4385655100C86803240 @default.
• W4385655100 hasConceptScore W4385655100C90059517 @default.
• W4385655100 hasIssue "S3" @default.
• W4385655100 hasLocation W43856551001 @default.
• W4385655100 hasLocation W43856551002 @default.
• W4385655100 hasOpenAccess W4385655100 @default.
• W4385655100 hasPrimaryLocation W43856551001 @default.
• W4385655100 hasRelatedWork W1780111622 @default.
• W4385655100 hasRelatedWork W2047415399 @default.
• W4385655100 hasRelatedWork W2150851104 @default.
• W4385655100 hasRelatedWork W2242047223 @default.
• W4385655100 hasRelatedWork W2384638857 @default.
• W4385655100 hasRelatedWork W2417539529 @default.
• W4385655100 hasRelatedWork W2419308557 @default.
• W4385655100 hasRelatedWork W2767548364 @default.
• W4385655100 hasRelatedWork W2928972849 @default.
• W4385655100 hasRelatedWork W3010122964 @default.
• W4385655100 hasVolume "7" @default.
• W4385655100 isParatext "false" @default.
• W4385655100 isRetracted "false" @default.
• W4385655100 workType "article" @default.